Description

Amgen’s Obesity Drug May Crush Novo Nordisk & Lilly With Just Four Shots A Year!

Amgen has reignited investor interest in the obesity drug space with its latest update on MariTide, a GLP-1 agonist that could reshape the competitive dynamics currently dominated by Eli Lilly and Novo Nordisk. In a Phase 2 study, MariTide helped patients maintain 17% to 18% weight loss into the second year—levels on par with current market leaders. However, Amgen is positioning MariTide as a superior offering with a differentiated edge: the potential for less frequent dosing—monthly or even quarterly—compared to the weekly injections required for Lilly and Novo’s therapies. In addition, Amgen highlighted a notably low incidence of nausea and vomiting, two common side effects in the GLP-1 class. While analysts noted the update was qualitative rather than quantitative, more detailed results are expected at the American Diabetes Association’s June 2026 meeting.